UK markets closed

Alnylam Pharmaceuticals, Inc. (ALNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
234.84-3.04 (-1.28%)
At close: 04:00PM EDT
234.00 -0.84 (-0.36%)
After hours: 06:38PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 29.71B
Enterprise value 28.64B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)14.70
Price/book (mrq)N/A
Enterprise value/revenue 14.29
Enterprise value/EBITDA -25.71

Trading information

Stock price history

Beta (5Y monthly) 0.37
52-week change 320.18%
S&P500 52-week change 318.96%
52-week high 3263.73
52-week low 3141.98
50-day moving average 3196.94
200-day moving average 3172.44

Share statistics

Avg vol (3-month) 31.02M
Avg vol (10-day) 3792.46k
Shares outstanding 5126.49M
Implied shares outstanding 6126.49M
Float 8125.94M
% held by insiders 10.42%
% held by institutions 192.21%
Shares short (15 Jul 2024) 44.49M
Short ratio (15 Jul 2024) 42.31
Short % of float (15 Jul 2024) 44.10%
Short % of shares outstanding (15 Jul 2024) 43.55%
Shares short (prior month 14 Jun 2024) 42.13M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -16.58%
Operating margin (ttm)-8.79%

Management effectiveness

Return on assets (ttm)-3.05%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)2B
Revenue per share (ttm)15.97
Quarterly revenue growth (yoy)54.80%
Gross profit (ttm)N/A
EBITDA -122.3M
Net income avi to common (ttm)-332.08M
Diluted EPS (ttm)-2.63
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)2.37B
Total cash per share (mrq)18.75
Total debt (mrq)2.68B
Total debt/equity (mrq)N/A
Current ratio (mrq)3.17
Book value per share (mrq)-1.73

Cash flow statement

Operating cash flow (ttm)189.12M
Levered free cash flow (ttm)172.9M